Ascribe Extends Integrated Pharmacy and Robotic IT Systems to Royal Bolton Hospital

Ascribe plc (AIM:ASP), the innovative health IT Group, today announced that it has successfully installed its Web Pharmacy solution at the Royal Bolton Hospital, part of the Bolton Hospitals NHS Trust and that the site is completely operational. One unique aspect of this 'Go Live' was that, on the same day that the hospital changed its pharmacy IT system, they also brought online a robotic dispensing system; thereby taking a massive leap forward in improving patient care and safety.

The Ascribe Web enabled pharmacy system is designed by healthcare clinicians to ensure higher patient safety standards. It achieves this by using a patient's medication record which effectively warns pharmacy staff automatically, via use of its integrated decision support service, if there may be a dangerous drug interaction or allergic reaction arising from the dispensed medications.

The Ascribe pharmacy system was selected by Bolton Hospital NHS Trust because it extends such a broad range of complementary pharmacy services outside of the dispensary. The system has been designed to allow ward-based clinical services, such as medicines management (whereby medicines can be ordered wirelessly from the wards) and electronic prescribing and medicine administration (which records exactly what medication was prescribed, when the medication was administered to the patient, and what reaction was noted). In addition to this, the Ascribe pharmacy system also provides the hospital pharmacy staff with a bi-directional interface from their pharmacy system to their Rowa Speedcase Robotic Dispensing unit, allowing pharmacists to both issue requests for prescriptions to their robotic system and receive (stock level) updates from their robot.

Brian Smith, Chief Pharmacist at the Royal Bolton Hospital said "The Bolton Hospitals NHS Trust is delighted that Ascribe was able to deliver such a robust and flexible pharmacy system within a twelve week project cycle. Our staff has welcomed the additional patient safety features that are embedded within the system and we look forward to extending our pharmacy services beyond the pharmacy itself, thereby saving time and providing a higher level of service to our clinicians and patients."

Stephen Critchlow, Executive Chairman of Ascribe plc said "Ascribe is delighted that the Royal Bolton has taken this step to improve patient safety standards. Our technology enables Hospitals to provide their clinicians with comprehensive and relevant information when and where healthcare decisions are made. This technology is in increasing demand and we have recently sold similar systems in the UK (at Addenbrookes Hospital, part of the Cambridge University Hospitals NHS Foundation Trust), and overseas in Australia & New Zealand."

For further information, please visit:
http://www.ascribe.com

About Ascribe
Ascribe plc is a leading healthcare company that develops and markets software solutions supporting patient, clinical and business processes to Primary & Secondary healthcare providers in the UK and overseas.

Ascribe is committed to providing technologies that improve patient safety standards and the company's solutions directly improve patient care and deliver financial savings to customers. The Group sells directly to hospitals and Primary Care Trusts rather than through centrally driven political initiatives.

The Group provides solutions to clinical professionals in all healthcare sectors; customers include Emergency and Minor Injuries Units, Mental Health and Social Care Units, Hospitals requiring patient administration systems (PAS) and medical equipment management, Hospital and Retail Pharmacies, and General Practice surgeries. Offering patient and decision support information to these clinicians in context with their activity is the key to the company's ongoing success.

Ascribe plc was floated on AIM in 2004, and currently employs over 220 personnel through its operating companies in the UK, Kenya, Australia and New Zealand.

For more information, please visit www.ascribe.com.

About Bolton Hospitals NHS Trust
Bolton Hospitals NHS Trust offers patients a wide range of services based at the Royal Bolton Hospital as well as some which take place in community settings. It is the Trust's aim to have the best hospital in the NHS by providing best possible care for our patients, improved health for local people, and joy and pride in work for our staff. Bolton Hospitals NHS Trust was formed in April 1994 and now serves the population of Bolton (around 265,000) plus some neighbouring areas. The Trust employs over 3,100 staff.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...